key: cord-0740132-79kmzdj0 authors: He, Qing; Gao, Hua; Tan, Dejiang; Zhang, Heng; Wang, Jun-zhi title: mRNA cancer vaccines: Advances, trends and challenges date: 2022-03-23 journal: Acta Pharm Sin B DOI: 10.1016/j.apsb.2022.03.011 sha: eeb1328a40042ee4b0afadb43e5e47c2e4d02119 doc_id: 740132 cord_uid: 79kmzdj0 Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the development of mRNA vaccines, mRNA cancer vaccines have become a research hotspot and have undergone rapid development, especially in the last five years. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, different administration routes, and preclinical evaluation, to reflect the trends and challenges associated with these vaccines. The vaccine was administered by intradermal injection. This vaccine significantly reduced immunosuppressive cells [e.g., Foxp3 + /CD4 + regulatory T cells (Tregs) in peripheral blood and myeloid suppressor cells] and increased specific T cells in a subset of patients. One treated patient had a complete response, and no adverse reactions greater than grade II occurred (NCT00204607). In 2011, Fotin-Mleczek et al. 72 Central immune tolerance to TAAs and peripheral immune tolerance (e.g., immune checkpoint pathways, TME) during tumor development are two major challenges Oberli et al. 77 showed that both LNP-containing mRNA encoding a single tumor antigen (e.g., gp100 or TRP2) and sequential therapy with the two antigens had significant antitumor effects in vivo; however, there was no significant difference between the antitumor effects of the two methods. The mRNA used to prepare vaccines mainly includes conventional nonreplicating Herpesvirus has a wide host range; can infect nerve cells, peripheral blood monocytes and DCs; and has a short replication cycle, a large capacity and relatively good safety [163] [164] [165] . In addition, other vectors, such as bacteria and yeast, have shown potential as vaccine vectors in preclinical studies [166] [167] [168] . On the whole, immunogenicity, carcinogenicity, infectivity, limited packaging capacities and difficulties in producing viral vectors are challenges to wide application. Developing mRNA delivery carriers with good safety, targeting, stability, selfadjuvant effects, load capacity and versatility that can efficiently and continuously deliver and present antigens and activate APCs has been a fundamental direction in the field of mRNA cancer vaccines. The carriers adopted for mRNA cancer vaccines in the preclinical setting are summarized in Table 3 Insert Table 3 One of the major vectors used in mRNA cancer vaccines is liposomes and their derivatives. In 1995, Conry et al. 41 al. 60 showed that Mann-capsules, prepared using polysaccharide-coated silica Dectin-2 or TLR-4 and that the ability of Mann-capsules to promote BMDC differentiation and maturation was significantly stronger than that of PEI or Lipofectamine; moreover, PEI and Lipofectamine were highly toxic. LNPs seem to be a promising carrier for delivery of mRNA cancer vaccines. The components of LNPs mainly include ionizable lipids, which facilitate self-assembly A major class of adjuvants [e.g., LPS 73 , poly(I:C) 73 The administration route has a direct effect on the efficacy of a vaccine, and the administration routes often adopted for use in mRNA cancer vaccines include intravenous, intradermal, subcutaneous, intramuscular, intranodal, and intratumoral administration. Intravenous administration allows for a larger vaccine volume and direct delivery of the vaccine into the lymphatic organs 171 but also carries a greater risk of systemic toxicity 172, 173 . The dermis into which the vaccine is intradermally injected contains APCs (e.g., DCs and macrophages) as well as vascular and lymphatic vessels 174, 175 but is mainly composed of dense connective tissue, resulting in a small vaccine volume when administered via the intradermal route. Intradermal delivery can also lead to adverse reactions at the injection site (e.g., swelling, pain, erythema and pruritus) 176 . The subcutis region into which the vaccine is subcutaneously injected contains fewer APCs than the dermis; however, it is mainly composed of a loose network of adipose tissues, permitting a larger injection volume via the subcutaneous route, which induces fewer local side effects (e.g., pain) 177,178 . The muscle into which a vaccine is intramuscularly injected contains dense blood networks that can help recruit and recirculate different types of immune cells (e.g., infiltrating APCs) to the injection site 179 . Intramuscular administration permits a relatively larger injection volume than the intradermal route and causes milder local side effects than the intradermal and subcutaneous routes 180 . Lymph nodes into which a vaccine is intranodally injected contain multiple APCs, and intranodal administration has a high delivery efficiency 181 , permits a small volume of vaccine, but involves complicated procedures 182 The TME is composed of immune cells, mesenchymal cells and various cytokines and tissue factors, which play an important role in tumorigenesis and immune escape 190, 191 . Interstitial pressure within a large mass can reduce the diffusion of large molecules (e.g., antibodies) and effector cells (e.g., T cells) 67 . Most solid tumors also lack T cell costimulatory molecules 192 . The TME often contains immunosuppressive cells, including CD4 + Tregs, MDSCs, suppressor CD8 + T cells, M2 TAMs and regulatory NK/NKT cells 193, 194 . These immunosuppressive cells and tumor cells in the TME can release a large number of soluble immunosuppressive factors, including transforming growth factor β, IL-10, PD-L1, indoleamine 2,3dioxygenase and vascular endothelial growth factor, into the microenvironment 195, 196 . With regard to tumor and HLA heterogeneity, the development of tumor neoantigen vaccines, which in theory have much stronger specific antitumor effects and weaker toxic side effects than TAA-directed vaccines, has been a leading hotspot in cancer vaccine research (discussed in Section 2.1.2). In view of the tumor immune microenvironment, the development of immune-based combination therapies (e.g., combination with adjuvants or immune checkpoint inhibitors) has been a key trend in the application of cancer vaccines (discussed in Sections 2.1.4 and 2.4). Preclinical evaluation of a product is a prerequisite to entering clinical translation, and reasonable evaluation can improve the reliability of predicted clinical outcomes. and target cell killing of CTLs); ⑥ humoral immunogenicity; ⑦ antitumor effect and associated mechanism; and ⑧ preliminary toxicities (e.g., cytotoxicity, visceral toxicity and hemolysis). Factors such as particle size, charge, the binding capability to mRNA and load rate, stability (e.g., time, temperature, and serum stability), PEGylation, and hardness can affect antigen delivery (e.g., lymphatic drainage). Son et al. 60 showed that Manncapsules ~220 nm in size had good deformability, and the recovery rate of the capsules after being passed through a 50 nm pore membrane was approximately 30%. DOTAP/DP7-C mRNA shows good serum stability and low cytotoxicity; however, Lipo2000 and PEI25K have strong cytotoxicity 59 . Finally, we look forward to the successful clinical translation of mRNA cancer vaccines. Jun-zhi Wang designed the study. Qing He and Heng Zhang collected the data and wrote the manuscript. Hua GAO, Dejiang Tan, and Jun-zhi Wang checked and revised the article. All of the authors have read and approved the final manuscript. The authors have no conflicts of interest to declare. Tables Table 1 An overview of mRNA cancer vaccines in preclinical and clinical settings 22, [40] [41] [42] [43] 45, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] . Key factor Stage mRNA cancer vaccine Antigens /targets Tumor-associated antigens (TAAs) phosphatase with tensin homology; Td, tetanus/diphtheria; VLVP, virus-like vaccine particle; WT1, Wilms' tumor 1. An unstable intermediate carrying information from genes to ribosomes for protein synthesis Direct gene transfer into mouse muscle in vivo Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors An mRNA vaccine against SARS-CoV-2-preliminary report Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection Nucleosidemodified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix) Therapeutic vaccine in chronically HIV-1-infected patients: a randomized, double-blind, placebo-controlled phase IIa trial with HTI-TriMix An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates A thermostable mRNA against COVID-19 An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Modified mRNA vaccines protect against Zika virus infection Immunogenicity and protection efficacy of a naked self-replicating mRNA-based Zika virus vaccine Selfamplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy An RNA toolbox for cancer immunotherapy Systemic delivery of factor IX messenger RNA for protein replacement therapy Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery offollistatin mRNA Targeted mRNA therapy for ornithine transcarbamylase deficiency A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates Vaccination with messenger RNA: a promising alternative to DNA vaccination mRNA vaccine for cancer immunotherapy mRNA vaccines-a new era in vaccinology Tailoring mRNA vaccine to balance innate/adaptive immune response Recent developments of RNA-based vaccines in cancer immunotherapy Overcoming HLA restriction in clinical trials: immune monitoring of mRNA-loaded DC therapy Mechanism of action of mRNAbased vaccines Towards personalized, tumour-specific, therapeutic vaccines for cancer The promise of mRNA vaccines: a biotech and industrial perspective A blocked structure at the 5′· terminus of mRNA from cytoplasmic polyhedrosis virus Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs Cationic liposome-mediated RNA transfection Induction of virusspecific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA Characterization of a messenger RNA polynucleotide vaccine vector Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity Mutant MHC class II epitopes drive therapeutic immune responses to cancer Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl activation Broadening the message: a nanovaccine co-loaded with messenger RNA and α-GalCer induces antitumor immunity through conventional and natural killer T cells DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine Sugar-nanocapsules imprinted with microbial molecular patterns for mRNA vaccination Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling Intranasal delivery of cationic liposomeprotamine complex mRNA vaccine elicits effective anti-tumor immunity BioNTech receives FDA fast track designation for its FixVac candidate BNT111 in advanced melanoma Therapeutic cancer vaccines Turning the corner on therapeutic cancer vaccines Advances in the development of personalized neoantigen-based therapeutic cancer vaccines Therapeutic cancer vaccines Vaccine strategy in melanoma RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy Multicomponent mannose-containing liposomes efficiently deliver RNA in murine immature dendritic cells and provide productive anti-tumour response in murine melanoma model Particlemediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma CD133 mRNAloaded dendritic cell vaccination abrogates glioma stem cell propagation in humanized glioblastoma mouse model An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia antigen-targeted dendritic cell vaccination Tolllike receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models Synthetic mRNA nanoparticlemediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen mRNA-based vaccines synergize with radiation therapy to eradicate established tumors Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide Virus-mimic mRNA vaccine for cancer treatment Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines Molecular and genetic properties of tumors associated with local immune cytolytic activity Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival Genomic correlates of immune-cell infiltrates in colorectal carcinoma Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Neoantigens in cancer immunotherapy Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia Actively personalized vaccination trial for newly diagnosed glioblastoma Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses mRNA-based therapeutics-developing a new class of drugs mRNA vaccines-a new era in vaccinology Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions Selfamplifying mRNA vaccines Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG Novel "anti-reverse" cap analogs with superior translational properties Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification mRNA transcript therapy Short poly(A) tails are a conserved feature of highly expressed genes Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells Regulation of poly(A) tail and translation during The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening A+U-rich instability elements differentially activate 5′-3′ and 3′-5′ mRNA decay Coordinate regulation of mRNA decay networks by GUrich elements and CELF1 Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells Insertion mutagenesis to increase secondary structure within the 5′ noncoding region of a eukaryotic mRNA reduces translational efficiency Codon bias and heterologous protein expression Developing mRNA-vaccine technologies Nucleoside modified mRNA vaccines for infectious diseases Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Acetylation of cytidine in mRNA promotes translation efficiency Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleosidemodified, protein-encoding mRNA HPLC purification of in vitro transcribed long RNA A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response Type I interferons modulate CD8 + T cell immunity to mRNA vaccines Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Galavotti CTL response, whereas long peptides induce sustained CTL reactivity Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Peptide vaccine: progress and challenges Therapeutic cancer vaccines New strategies for therapeutic cancer vaccines Dendritic cells in cancer immunotherapy Current applications and future prospects of nanotechnology in cancer immunotherapy Emerging cancer vaccines: the promise of genetic vectors Therapeutic cancer vaccines: current status and moving forward Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia The expanding spectrum of herpesvirus infections of the nervous system Herpesvirus BACs: past, present, and future Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen Optimization of the linker length of mannose-cholesterol conjugates for enhanced mRNA delivery to dendritic cells by liposomes Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters A good practice guide to the administration of substances and removal of blood mRNA vaccine delivery using lipid nanoparticles Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey Antigen-presenting cells in the skin Immunogenicity of RNA replicons encoding HIV env immunogens designed for self-assembly into nanoparticles Local side effects of subcutaneous and intramuscular urinary gonadotropins for ovarian stimulation in in vitro fertilization: a prospective, randomized study Subcutaneous and visceral adipose tissue: structural and functional differences Formulation and delivery technologies for mRNA vaccines Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques Beyond antigens and adjuvants: formulating future vaccines Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice Intralymphatic immunotherapy and vaccination in mice Therapeutic cancer vaccines: past, present, and future mRNA cancer vaccines-messages that prevail Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations T-Cell epitope discovery for therapeutic cancer vaccines More than one reason to rethink the use of peptides in vaccine design Definition of supertypes for HLA molecules using clustering of specificity matrices Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment Cancer immunoediting: from immunosurveillance to tumor escape Features of responding T cells in cancer and chronic infection Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre-versus postvaccination Natural innate and adaptive immunity to cancer Less yin, more yang: confronting the barriers to cancer immunotherapy Delivering the messenger: advances in technologies for therapeutic mRNA delivery PSMA/STEAP 72 , TRP2/WT1/P1A 73 , total tumor RNA 74 , thymus cell antigen 1a/truncated nerve growth factor receptor/TRP2 75 Clinical PSA 43 ; PSA, prostate stem cell antigen, PSMA, and STEAP1 (NCT00831467) NCT01817738); autologous tumor mRNA 81 ; AML lysate plus mRNA (NCT00514189); tumor stem cell-derived mRNA 82 ; mRNA from primary prostate cancer tissue, hTERT, and surviving (NCT01197625); hTERT and LAMP (NCT00510133); amplified OC stem cell mRNA, hTERT and surviving (NCT01334047); hTERT, surviving and tumor cell-derived mRNA TRP2 (NCT01456104); MUC1 and survivin 84 ; NY-ESO-1, MAGE-A3, tyrosinase, and TPTE 85 (NCT04526899); suppressor of cytokine signaling-1, MUC1 and surviving OC TAAs (NCT04163094); 5 PC TAAs (NCT04382898); fixed combination of shared cancer antigens (NCT04534205) CEA (NCT00529984, NCT01890213); personalized TAA panels 89 Tumor-specific antigens (TSAs) Preclinical Poly-neo-epitope 48 , neoantigens 22 , HPV E6/E7 22 , HPV E7 52 Clinical CMV pp65-LAMP (NCT02529072); neoantigens 91 , Kirsten rat sarcoma viral oncogene mutated proteins (NCT03948763) IL-23 and IL-36γ) mRNA-2752 (human OX40L, IL-23 and IL-36γ) (NCT02872025, NCT03739931), mRNA-2416 (human OX40L) (NCT03323398) protamineformulated 101 , cationic lipids 48 , mannosylated liposomes 74 , lipid mRNA particles 75 , lipoplexes 22 , a cell-penetrating peptide rich in the arginine peptide amphiphile RALA motif 102 Langerhans-type DCs (NCT01456104), protamine (RNActive ® ) FLT3 105 , LPS/poly(I:C) 73 , TriMix 73,90 , cholera toxin CV8102 (NCT03291002, NCT03203005), mRNA-2752 (NCT02872025, NCT03739931), mRNA-2416 (NCT03323398), BNT131 (NCT03871348), MEDI1191 (NCT03946800) Administration routes Abbreviations: AML, acute myelogenous leukemia; α-GC, α-galactosylceramide BisCCL2/5i, an antibody that bispecifically binds and neutralizes CCL2 and CCL5; CEA, carcinoembryonic antigen; CMV pp65, cytomegalovirus phosphor protein 65; CpG, cytosine-guanine cytosine-phosphate-guanine Fms-like tyrosine kinase 3; GM-CSF, granulocyte-macrophage colony-stimulating factor; gp, glycoprotein hTERT, human telomerase reverse transcriptase gene HPV, human papilloma virus LAMP1, lysosomal-associated membrane protein 1; LPS, lipopolysaccharide; MART1, melanoma antigen recognized by T cells MAGE, melanoma-associated antigen; MUC1, mucin 1; NY-ESO-1, New York esophageal squamous cell carcinoma 1; NKT, natural killer T cell OC, ovarian cancer; PC, prostate cancer; poly(I:C), polyinosinic:polycytidylic acid PSA, prostate-specific antigen PSMA, prostate-specific membrane antigen; PRAME, preferentially expressed antigen in melanoma; PTEN, phosphatase and tensin homolog deleted on chromosome ten STEAP, six-transmembrane epithelial antigen of prostate TLR, Toll-like receptor TRP, tyrosinase-related protein